Credit Suisse’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-250,553
| Closed | -$23.3M | – | 4530 |
|
|
2021
Q4 | $23.3M | Sell |
250,553
-588,280
| -70% | -$38.8M | 0.01% | 1014 |
|
|
2021
Q3 | $50M | Buy |
838,833
+10,449
| +1% | +$617K | 0.03% | 644 |
|
|
2021
Q2 | $56.5M | Buy |
828,384
+1,984
| +0.2% | +$129K | 0.03% | 618 |
|
|
2021
Q1 | $57.3M | Sell |
826,400
-27,672
| -3% | -$2.13M | 0.03% | 647 |
|
|
2020
Q4 | $65.6M | Buy |
854,072
+291,814
| +52% | +$21.9M | 0.03% | 585 |
|
|
2020
Q3 | $42.1M | Sell |
562,258
-6,940
| -1% | -$463K | 0.03% | 684 |
|
|
2020
Q2 | $35.8M | Buy |
569,198
+115,617
| +25% | +$6.36M | 0.03% | 681 |
|
|
2020
Q1 | $19.1M | Sell |
453,581
-25,105
| -5% | -$1.15M | 0.02% | 867 |
|
|
2019
Q4 | $21.7M | Buy |
478,686
+51,051
| +12% | +$2.41M | 0.02% | 967 |
|
|
2019
Q3 | $19.6M | Buy |
427,635
+19,708
| +5% | +$1.11M | 0.02% | 928 |
|
|
2019
Q2 | $23.9M | Sell |
407,927
-37,484
| -8% | -$1.94M | 0.02% | 828 |
|
|
2019
Q1 | $20M | Buy |
445,411
+4,272
| +1% | +$196K | 0.02% | 865 |
|
|
2018
Q4 | $17.2M | Buy |
441,139
+7,193
| +2% | +$282K | 0.02% | 869 |
|
|
2018
Q3 | $20M | Buy |
433,946
+96,064
| +28% | +$3.89M | 0.02% | 878 |
|
|
2018
Q2 | $14.7M | Sell |
337,882
-244,256
| -42% | -$10.5M | 0.01% | 1013 |
|
|
2018
Q1 | $23M | Buy |
582,138
+230,318
| +65% | +$8.96M | 0.02% | 774 |
|
|
2017
Q4 | $12M | Buy |
351,820
+280,020
| +390% | +$7.98M | 0.01% | 1152 |
|
|
2017
Q3 | $1.83M | Buy |
71,800
+15,012
| +26% | +$344K | ﹤0.01% | 2615 |
|
|
2017
Q2 | $958K | Buy |
56,788
+17,193
| +43% | +$236K | ﹤0.01% | 2732 |
|
|
2017
Q1 | $577K | Buy |
39,595
+10,317
| +35% | +$153K | ﹤0.01% | 3194 |
|
|
2016
Q4 | $416K | Buy |
29,278
+473
| +2% | +$7.33K | ﹤0.01% | 3528 |
|
|
2016
Q3 | $504K | Sell |
28,805
-4,204
| -13% | -$69.7K | ﹤0.01% | 3413 |
|
|
2016
Q2 | $565K | Buy |
33,009
+2,585
| +8% | +$46.2K | ﹤0.01% | 3345 |
|
|
2016
Q1 | $601K | Buy |
30,424
+10,444
| +52% | +$167K | ﹤0.01% | 3117 |
|
|
2015
Q4 | $379K | Sell |
19,980
-4,192
| -17% | -$85.5K | ﹤0.01% | 3555 |
|
|
2015
Q3 | $463K | Sell |
24,172
-27,522
| -53% | -$935K | ﹤0.01% | 3456 |
|
|
2015
Q2 | $2.4M | Buy |
51,694
+25,200
| +95% | +$1.09M | ﹤0.01% | 2403 |
|
|
2015
Q1 | $1.16M | Sell |
26,494
-31,251
| -54% | -$1.45M | ﹤0.01% | 2854 |
|
|
2014
Q4 | $2M | Buy |
57,745
+27,711
| +92% | +$1.12M | ﹤0.01% | 2529 |
|
|
2014
Q3 | $1.26M | Sell |
30,034
-40,671
| -58% | -$1.82M | ﹤0.01% | 2858 |
|
|
2014
Q2 | $4.14M | Buy |
70,705
+34,924
| +98% | +$2.2M | ﹤0.01% | 2121 |
|
|
2014
Q1 | $2.25M | Sell |
35,781
-50,856
| -59% | -$3.37M | ﹤0.01% | 2415 |
|
|
2013
Q4 | $5.07M | Buy |
86,637
+1,726
| +2% | +$90.2K | ﹤0.01% | 1839 |
|
|
2013
Q3 | $4.47M | Sell |
84,911
-22,088
| -21% | -$1.48M | ﹤0.01% | 1733 |
|
|
2013
Q2 | $8.24M | Buy |
+106,999
| New | +$8.73M | 0.01% | 1254 |
|
Credit Suisse's ARNA Position: Q1 2022 in Review
Credit Suisse sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 250,553 shares — an estimated $23.3M sold.
Credit Suisse first reported a position in ARNA in Q2 2013 and held it in 35 quarters. The position peaked at $65.6M in Q4 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Credit Suisse reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Credit Suisse sold 250,553 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $23.3M.
- Credit Suisse first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- Credit Suisse's Arena Pharmaceuticals Inc position peaked at $65.6M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Credit Suisse's 13F filing for Q1 2022, filed 16 May 2022.